Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Abaloparatide

Tymlos · PTHrP Analog

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

Abaloparatide has strong randomized evidence for its approved osteoporosis indication, anchored by the phase 3 ACTIVE trial (2,463 postmenopausal women, placebo-controlled, 86% relative reduction in new vertebral fractures and 43% reduction in nonvertebral fractures), the ACTIVExtend sequence through alendronate sustaining fracture reduction over 43 months, and the ATOM trial supporting the 2022 approval in men. It falls short of grade 5 because the pivotal base is a small number of trials for a single anabolic agent with a lingering osteosarcoma caution, and any longevity or general bone-preservation use beyond osteoporosis is unsupported.

FDA
FDA Approved (Tymlos), postmenopausal women 2017 and men at high fracture risk 2022; osteosarcoma boxed warning later removed
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Cumulative-use duration guidance and residual osteosarcoma caution (boxed warning removed); orthostatic hypotension, dizziness, hypercalciuria; high cost.

Talk to a clinician before taking this, particularly if you have a thyroid condition. The Atlas can tell you what has been studied about Abaloparatide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A PTHrP analog FDA-approved to build bone in postmenopausal women (2017) and later in men (2022) with osteoporosis at high fracture risk. Its anabolic action draws bone-health interest, though use is limited to the approved osteoporosis setting.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Osteoporosis (approved)
  • Bone-density optimization
Osteoporosis in postmenopausal women at high fracture risk
FDA-approved in 2017 to build bone and reduce fracture risk in postmenopausal women with osteoporosis at high risk for fracture.
Osteoporosis in men at high fracture risk
FDA-approved in 2022 to increase bone density in men with osteoporosis at high fracture risk, based on the ATOM study.

How it works

Abaloparatide is a bone-building drug, one of the few that actually adds new bone rather than just slowing its loss. It is a synthetic copy of a natural protein closely related to parathyroid hormone, and given as a small daily injection it switches on the bone-forming cells. The trick is timing: a brief daily pulse on the parathyroid receptor tips the constant cycle of bone breakdown and rebuilding toward building, so density and strength rise and fractures become less likely.

Abaloparatide is a synthetic analog of parathyroid-hormone-related protein, the PTHrP(1-34) fragment, closely related to teriparatide’s PTH(1-34) but with several amino-acid changes. It acts on the same parathyroid hormone receptor and is given by daily injection. It is sold as Tymlos.

Type
PTHrP(1-34) analog
Class
Anabolic (bone-building)
Target
Parathyroid receptor
Dosing
Daily injection
Vs teriparatide
More hip bone, less calcium
Approved
Yes (Tymlos)

Teriparatide’s Sibling, Tuned To Build More Bone

Abaloparatide belongs to a small, valuable class: the anabolic, or bone-building, osteoporosis drugs, which are the opposite of the far more common drugs that merely slow bone loss. It is the close sibling of teriparatide, hitting the same parathyroid receptor, but it is tuned differently. By favoring a more transient signal at that receptor, it drives bone formation while stirring up less bone breakdown and less calcium release, and in practice it raises bone density faster and further, particularly at the hip, where teriparatide is weaker, with fewer episodes of high calcium. Approved first for postmenopausal women at high fracture risk and later for men, it is a genuine, evidence-backed refinement rather than a me-too. The honest caveats are shared with its class: it still carries a boxed warning based on a bone-tumor signal seen in rats given high doses, with use capped at two years of lifetime parathyroid-analog therapy. Notably, teriparatide’s equivalent warning was removed in 2020 after long human experience showed no excess risk, while abaloparatide’s has lagged behind. It also requires a daily injection and can briefly lower blood pressure on standing.

Safety in detail

Approved use is osteoporosis at high fracture risk only; the earlier osteosarcoma boxed warning (based on rat data) has been removed from the label, though osteosarcoma is retained as a caution and cumulative-duration guidance still applies. No approved or evidence-backed anti-aging or general longevity indication exists.

  • It carries a boxed warning based on a dose-dependent bone-tumor signal in rats, with use capped at two years of lifetime parathyroid-analog therapy.
  • It is contraindicated in people at increased osteosarcoma risk, including those with open growth plates, bone metastases or prior skeletal radiation.
  • It can cause orthostatic hypotension, a brief blood-pressure drop on standing, usually within four hours of injection.
  • Other effects include high urine calcium, dizziness, nausea and palpitations, and it requires daily injection with calcium and vitamin D.
  • It causes less calcium elevation than teriparatide, a relative advantage.

Children and teenagers

Abaloparatide is not for pediatric use and is contraindicated in anyone with open growth plates because of the osteosarcoma risk, which applies to children and adolescents. Osteoporosis is an adult and aging condition, so there is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Abaloparatide’s economy is a legitimate branded one: a specialty anabolic for high-risk osteoporosis, sold as a daily-injection pen. The market is smaller than that of the bone-loss-slowing drugs but higher in per-patient value, and its commercial story is straightforward approved medicine.

How we got here

Abaloparatide is a synthetic analog of parathyroid-hormone-related protein, PTHrP(1-34), developed as an anabolic osteoporosis therapy. Radius Health won U.S. FDA approval for it under the brand Tymlos in 2017. It carries the brand name Eladynos in the European Union and other markets.

After teriparatide became the first bone-building osteoporosis drug, abaloparatide was developed as a refined analog of the related protein, tuned to build bone with less calcium disturbance. The FDA approved it for postmenopausal women in 2017 and for men in 2022. Teriparatide’s rat-derived boxed warning was removed in 2020 after long human experience, while abaloparatide’s has lagged, and the anabolic class has since grown to include romosozumab.

  1. 2002Teriparatide becomes the first anabolic osteoporosis drug.
  2. 2017The FDA approves abaloparatide for postmenopausal women.
  3. 2020Teriparatide’s rat-derived boxed warning is removed.
  4. 2022The FDA approves abaloparatide for men with osteoporosis.
  5. ongoingThe anabolic class grows, and the warning question lingers.

The numbers behind the grade

Type
PTHrP(1-34) analog
Class
Anabolic
Dosing
Daily injection
Vs teriparatide
More hip bone
Approved
Yes
Brand
Tymlos

The people taking it

The second anabolic, bone-building osteoporosis drug, a refined parathyroid-related-protein analog that builds bone faster and with less calcium trouble than teriparatide, approved for high-fracture-risk women and men.

Abaloparatide’s users are postmenopausal women and men with severe, high-fracture-risk osteoporosis, especially those who have already fractured, carry multiple risk factors, or cannot use the bone-loss-slowing drugs. They are typically older and managed by endocrinology or osteoporosis specialists.

Approved for high-fracture-risk osteoporosis in postmenopausal women and men, a daily-injection anabolic that actively builds bone. The refined sibling of teriparatide.

Set against the alternatives

The defining comparison is to teriparatide: both are anabolic agents acting on the same parathyroid receptor, one built from parathyroid hormone and the other from the related protein, but abaloparatide is the refined sibling, with faster, greater bone-density gains at the hip and less calcium elevation, while teriparatide is older, now generic, and has had its boxed warning removed. Against romosozumab, a newer anabolic given as a twelve-month course by a different mechanism, it is part of a small but growing bone-building class. And against the antiresorptives like bisphosphonates and denosumab, which slow bone loss rather than build bone, the anabolics are reserved for high-risk osteoporosis, often followed by an antiresorptive to hold the gains. Its strength is a real, well-tuned improvement; its limits are the class cautions.

What we do not know

  • Whether its boxed warning will be removed, as teriparatide’s was in 2020.
  • The optimal sequence of anabolic therapy followed by a bone-loss-slowing drug.
  • Its place relative to romosozumab in the anabolic class.
  • Longer-term and cumulative-use questions.

What could change

Warning removalIts boxed warning may follow teriparatide’s in being removed.Sequencing strategyAnabolic-then-antiresorptive sequencing is refined to hold gains.Alternative deliveryA transdermal-patch version has been explored.Growing classThe small anabolic class continues to expand.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Abaloparatide is a prescription anabolic osteoporosis drug obtained through an endocrinologist or osteoporosis specialist, the legitimate route, for high-fracture-risk osteoporosis. It is not a gray-market or consumer compound, and the two-year limit, boxed warning and daily injection are part of proper use. It is a real, evidence-backed medicine.

As a branded drug with no generic, abaloparatide is expensive, though it is typically covered by insurance for appropriate high-risk patients. It is a high-value specialty medicine.

Abaloparatide comes from regulated pharmaceutical manufacturing as a branded prescription product with full quality assurance.

Branded pharmaceuticalIt is supplied as a branded daily-injection pen with no generic.Specialty prescriptionIt is prescribed within osteoporosis and endocrine care.Standard regulated supplyIt moves through normal pharmaceutical channels.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Abaloparatide.

Nothing outstanding on this one.

Sources

The studies that matter

  • Anabolic mechanismestablished

    A brief daily pulse on the parathyroid receptor drives bone-forming cells, tipping remodeling toward building.

  • Refined signalingcomparative studies

    Abaloparatide favors a more transient receptor signal, producing more bone formation with less resorption and less calcium release than teriparatide.

  • Bone and fracture dataPhase 3

    Trials showed faster, greater bone-density gains, especially at the hip, and reduced vertebral and non-vertebral fractures.

  • Approvals2017-2022

    The FDA approved it for postmenopausal women in 2017 and for men in 2022.

  • Class warningongoing

    It carries the class boxed warning from a rat bone-tumor signal, while teriparatide’s identical warning was removed in 2020.